Iron Overload Cardiomyopathy in Clinical Practice

On T2* Magnetic Resonance and Cardiac Iron

(2011) John-Paul Carpenter et al.   CIRCULATION

Cardiac iron and cardiac disease in males and females with transfusion-dependent thalassemia major: a T2* magnetic resonance imaging study

(2011) M. Marsella et al.   HAEMATOLOGICA

Iron-Chelating Therapy for Transfusional Iron Overload

(2011) Gary M. Brittenham   NEW ENGLAND JOURNAL OF MEDICINE

β-Thalassemia Cardiomyopathy

(2010) Dimitrios T. Kremastinos et al.   Circulation-Heart Failure

Early Detection of Left Ventricular Dysfunction with Strain Imaging in Thalassemia Patients

(2010) Ahmet Kaya Bilge et al.   CLINICAL CARDIOLOGY

Relation of myocardial T2* to right ventricular function in thalassaemia major

(2010) F. Alpendurada et al.   EUROPEAN HEART JOURNAL

Continued improvement in myocardial T2* over two years of deferasirox therapy in  -thalassemia major patients with cardiac iron overload

(2010) D. J. Pennell et al.   HAEMATOLOGICA

Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging

(2010) A. Pepe et al.   HAEMATOLOGICA

A phase 1 dose-escalation study: safety, tolerability, and pharmacokinetics of FBS0701, a novel oral iron chelator for the treatment of transfusional iron overload

(2010) H. Y. Rienhoff et al.   HAEMATOLOGICA

Iron-Overload Cardiomyopathy: Pathophysiology, Diagnosis, and Treatment

(2010) Colm J. Murphy et al.   JOURNAL OF CARDIAC FAILURE

Iron Overload Cardiomyopathy

(2010) Pradeep Gujja et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM

(2010) Christian Rose et al.   LEUKEMIA RESEARCH

Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study

(2010) Norbert Gattermann et al.   LEUKEMIA RESEARCH

Predictive value of B-type natriuretic peptides in detecting latent left ventricular diastolic dysfunction in β-thalassemia major

(2009) Dimitrios Th. Kremastinos et al.   AMERICAN HEART JOURNAL

Efficacy of deferasirox in reducing and preventing cardiac iron overload in  -thalassemia

(2009) D. J. Pennell et al.   BLOOD

Improving survival with deferiprone treatment in patients with thalassemia major: A prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies

(2009) Aurelio Maggio et al.   BLOOD CELLS MOLECULES AND DISEASES

History and Current Impact of Cardiac Magnetic Resonance Imaging on the Management of Iron Overload

(2009) John C. Wood   CIRCULATION

Cardiac T2* Magnetic Resonance for Prediction of Cardiac Complications in Thalassemia Major

(2009) P. Kirk et al.   CIRCULATION

2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults

(2009) et al.   CIRCULATION

Myocardial scarring by delayed enhancement cardiovascular magnetic resonance in thalassaemia major

(2009) A Pepe et al.   HEART

Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency

(2009) Stefan D. Anker et al.   NEW ENGLAND JOURNAL OF MEDICINE

Consensus statement on iron overload in myelodysplastic syndromes

(2008) John M. Bennett et al.   AMERICAN JOURNAL OF HEMATOLOGY

Cardiac iron across different transfusion-dependent diseases

(2008) John C. Wood   BLOOD REVIEWS

ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM)

(2008) et al.   EUROPEAN HEART JOURNAL